Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia
Status:
Not yet recruiting
Trial end date:
2023-01-29
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and
decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of
human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to IL3 receptor
positive cancer cells in a targeted way and delivers DT388 to kill them. Chemotherapy drugs,
such as decitabine, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
tagraxofusp and decitabine may help to control the disease in patients with chronic
myelomonocytic leukemia.